Anlotinib also targets fibroblast growth factor receptors (FGFR1 to FGFR4), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-Kit (stem cell factor receptor), which are involved in tumor proliferation, survival, and resistance mechanisms. This evidence concerns the gene PDGFRB and neoplasm.